Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2b (UGT2B)

a technology of uridine diphosphate and glucuronosyltransferase, which is applied in the direction of biocide, drug composition, metabolic disorder, etc., can solve the problems of reducing the clearance rate of liver cells, affecting the ability of liver cells to function normally, so as to increase the bioavailability of morphine-like analgesic agents.

Inactive Publication Date: 2016-06-30
NAT DEFENSE MEDICAL CENT
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention provides a new UGT2B inhibitor that can increase the bio-availability of morphine-like analgesic agents by inhibiting the enzyme UGT2B. This inhibitor can be combined with morphine-like agents and a pharmaceutically acceptable carrier to create a pharmaceutical composition. The invention also provides a new UGT2B enhancer that can increase the clearance rate of morphine-like analgesic agents by enhancing the activity of UGT2B. These inhibitors and enhancers can improve the effectiveness of morphine-like agents and reduce the risk of side effects.

Problems solved by technology

Therefore, the glucuronidation will be hampered by defected UGTs activities in individuals who suffered from liver diseases.
Consequently, the liver's lower clearance rate in metabolizing drug will increase the toxic reaction and the rate of carcinogenesis in an individual with liver diseases.
Since the aforementioned UGT inhibitors are active drug ingredients by themselves and will induce prominent physical responses, they are not good candidates as drug absorption enhancers.
The drawback of this drug is its poor absorbability when delivered orally.
However, the issues about what are the herbal medicines that can inhibit UGT and how to apply them to the UGT-related therapeutic usages are still need to be addressed.
However, there is no evidence showing that solutol HS15 at such concentration has any impact on the intact of the cell under light microscope.
Unfortunately, most of these chemicals are fat-soluble compound, thus, different excipients are added to improve solubility and stability of these chemicals.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2b (UGT2B)
  • Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2b (UGT2B)
  • Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2b (UGT2B)

Examples

Experimental program
Comparison scheme
Effect test

experiment 1

In Vitro Experiment of UGT2B Inhibitor

Material and Method

1. The Preparation of UGT2B Inhibitor

[0076]In the following experiment, 27 different kinds of CHEs and 10 different excipients were used as UGT2B inhibitor in this invention. These CHEs are pure compounds available commercially, and were purchased from Sigma Chemical Co., Nacalai Tesque (Kyoto, Japan) and Indofine Chemical Co., Inc. (Somerville, N.J.). Their category, name, source and chemical formula are listed in Table 1. These UGT2B inhibitors are dissolved in alcohol at the concentration of 1, 10, 100 μM for the following experiment.

[0077]Besides, these excipients are commercially available pure compounds, they are PEG (Polyethylene glycol) 400, PEG 2000, PEG 4000, Tween 20, Tween 60, Tween 80, BRIJ® 58, BRIJ® 76, Pluronic® F68, Pluronic® F127. These excipients are dissolved in water and make up to 0.5%, 5%, 50% (wt %, w / v) for the following experiment. (Note: BRIJ is a registered trademark of ICI Americas, Inc.; Pluronic ...

experiment 2

In Virto Experiment of UGT2B Enhancer

[0103]This experiment uses the same protocol described in Experiment 1, except by testing the 40 CHEs listed in Table 5 as the UGT2B enhancer. Those CHEs are commercially available pure compounds, acquired from Sigma Chemical Co., Nacalai Tesque (Kyoto, Japan) and Indole Chemical Co. Inc (Somerville, N.J. Their categories, names, sources, and chemical compositions are described in Table 5.

TABLE 5Category, name, source, and chemical composition of the UGT2B enhancers.SourceChemical formula andCategoryName(scientific name)molecular weightFlavonoidGenkwaninArtemisiae cpillaris herbaApigeninChamomillaeflosLuteolinDigitals foliumLuteolin-7- GlucosideDigitals foliumHomoorientinSwertiae herbaIsovitexinSwertiae herbaNeohesperidinAurantii fructusimmaturusFormononetinAstragali radixKaempferolSennae foliumIsoquercitrinHydrangeaedulcis folium6-GingerolZingiberisLiquiritinGlycyrrizae radixnaringeninAurantii fructusimmaturusUmbelliferoneAurantii fructusimmatur...

experiment 3

The Effect of UGT2B Inhibitors on the Concentration of Nalbuphine Taken Orally

Material and Methods:

1. Experimental Animal

[0105]Healthy male Sprague-Dawley rat, weight 500-600 g, acquired from National Laboratory Animal Breeding and Research Center in Taiwan, are used. After the acquisition, the animals are kept in a room with constant temperature (at 25±1° C.), humidity and day light (12 hours per day) for one week. Before the experiment, the animals are fasted for 12-16 hours. The drugs are administered orally.

2. Preparation of UGT2B Inhibitor and Nalbuphine Solution

[0106]Standard solution of nalbuphine is dissolved in water, and all inhibitors are dissolved in alcohol.

3. Methods:

[0107]i. Anesthetize the rat with 3-5 mg / 100 g body weight of pentobarbital intraperitoneally (I.P.). The rat will be anesthetized in about 20˜30 min.[0108]ii. Insert the PE-50 catheter tube into external jugular vein to sample the blood.[0109]iii. Orally administered 6 rats with UGT2B inhibitor—capillaris...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
half lifeaaaaaaaaaa
weightaaaaaaaaaa
wt %aaaaaaaaaa
Login to View More

Abstract

A UGT2B inhibitor capable of increasing the bio-availability of a drug, is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: capillarisin, isorhamnetin,β-naphthoflavone, α-naphthoflavone, hesperetin, terpineol, (+)-limonene, β-myrcene, swertiamarin, eriodictyol, cineole, apigenin, baicalin, ursolic acid, isovitexin, lauryl alcohol, puerarin, trans-cinnamaldehyde, 3-phenylpropyl acetate, isoliquritigenin, paeoniflorin, gallic acid, genistein, glycyrrhizin, protocatechuic acid, ethyl myristate, umbelliferone, PEG (Polyethylene glycol) 400, PEG 2000, PEG 4000, Tween 20, Tween 60, Tween 80, BRIJ® 58, BRIJ® 76, Pluronic® F68, Pluronic® F127, and a combination thereof. A UGT2B enhancer capable of enhancing a clearance rate of morphine-like analgesic agents, is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: nordihydroguaiaretic acid, wogonin, trans-cinnamic acid, baicalein, quercetin, daidzein, oleanolic acid, homoorientin, hesperetin, narigin, neohesperidin, (+)-epicatechin, hesperidin, liquiritin, eriodictyol, formononetin, quercitrin, genkwanin, kaempferol, isoquercitrin, (+)-catechin, naringenin, daidzin, (−)-epicatechin, luteolin-7-glucoside, ergosterol, rutin, luteolin, ethyl myristate, apigenin, 3-phenylpropyl acetate, umbelliferone, glycyrrhizin, protocatechuic acid, poncirin, isovitexin, 6-gingerol, cineole, genistein, trans-cinnamaldehyde, and a combination thereof.

Description

RELATED APPLICATIONS[0001]The present application is a continuous application of Ser. No. 12 / 325,139, filed on Nov. 28, 2008, which is a continuation-in-part of Ser. No. 11 / 028,615, filed on Jan. 5, 2005.BACKGROUND OF THE INVENTION[0002]1. Field of the Invention[0003]This invention aims at enhancing drug bio-availability by providing an effective UGT2B inhibitor as well as a UGT2B enhancer for increasing the detoxification ability of individuals.[0004]2. Description of the Prior Art[0005]The drug metabolism process in human body, especially the metabolism of high fat-soluble drugs, includes two biotransformation steps: phase I reaction that catalyzes fat-soluble molecules to polarized molecules, and phase II reaction that produces highly polarized molecule through conjugation, such that the drugs can be metabolized efficiently and excreted to urine or feces.[0006]The most common and important conjugation is glucuronidation by uridine diphosphate (UDP)-glucuronosyltransferases (refer...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/485A61K31/37A61K31/7048A61K31/192A61K31/704A61K31/366A61K31/19A61K31/353A61K31/11
CPCA61K31/485A61K31/353A61K31/37A61K31/7048A61K31/192A61K31/704A61K31/366A61K31/19A61K31/11A61K31/225A61K31/57A61P3/00
Inventor OLIVER, YOA-PU HUHSIONG, CHENG-HUEIWANG, MEI-TINGPAO, LI-HENG
Owner NAT DEFENSE MEDICAL CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com